Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 5/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209782 | 1.00 | DUT (0.48) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL19687652 | 1.00 | DUT (0.48) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL19687651 | 1.00 | DUT (0.48) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL13282414 | 1.00 | DUT (0.48) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL12015134 | 0.89 | DUT (0.47) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL26268704 | 0.89 | DUT (0.47) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL12087561 | 0.89 | DUT (0.47) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL22996114 | 0.89 | DUT (0.46) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL18573361 | 0.89 | DUT (0.46) | DUTP2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL23343339 | 0.88 | SLC28A1 (0.52) | DUTP2RY2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4261284-A1 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | Fukuoka University (JP) | 2023-10-18 | — | — | EP | disclosed |
| EP-3981436-A1 | STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO | Fukuoka University (JP) | 2022-04-13 | — | — | EP | disclosed |
| US-20210032282-A1 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | AIST (JP) | 2021-02-04 | — | — | US | disclosed |
| WO-2020246560-A1 | STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO | 学校法人福岡大学 | 2020-12-10 | — | — | WO | disclosed |
| US-20170349623-A1 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349623-A1 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349623-A1 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | POLRMT, POLN, POLM | DUT 163/4885P2RY2 3263/4885P2RY4 3843/4885 |
| US-20210032282-A1 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | POLRMT, POLN, POLM | DUT 163/4885P2RY2 3263/4885P2RY4 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.